1. Homepage
  2. Equities
  3. Switzerland
  4. Swiss Exchange
  5. Basilea Pharmaceutica AG
  6. News
  7. Summary
    BSLN   CH0011432447

BASILEA PHARMACEUTICA AG

(BSLN)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Basilea-Pfizer's Cresemba Gets China's Approval to Treat Another Fungal Infection

01/13/2022 | 01:32am EDT


© MT Newswires 2022
Stocks mentioned in the article
ChangeLast1st jan.
BASILEA PHARMACEUTICA AG 3.00% 32.6 Delayed Quote.-20.33%
ON SEMICONDUCTOR CORPORATION 0.70% 56.46 Delayed Quote.-16.87%
PFIZER, INC. 3.59% 52.47 Delayed Quote.-11.14%
All news about BASILEA PHARMACEUTICA AG
04/27Basilea Pharmaceutica Licenses Antifungal Program From US-based Fox Chase
MT
04/27Basilea announces licensing of a novel first-in-class antifungal program from Fox Chase..
AQ
04/27Basilea Pharmaceutica AG Announces Licensing of Novel First-In-Class Antifungal Program..
CI
04/13Basilea shareholders approve all proposals of the board of directors at the annual gene..
GL
04/13Basilea Pharmaceutica Ltd. Approves Appointment of Leonard Kruimer as New Member of Boa..
CI
04/13Basilea's Oncology Drug Candidates Show Anti-Cancer Activity in Preclinical Trial
MT
04/13Basilea reports preclinical data on oncology drug candidates BAL0891, derazantinib and ..
AQ
04/13Basilea Pharmaceutica Ltd. Reports Preclinical Data on Oncology Drug Candidates BAL0891
CI
03/30BASILEA PHARMACEUTICA : Updated March 30, 2022
PU
03/16BASILEA PHARMACEUTICA : Shareholder letter EN
PU
More news
Analyst Recommendations on BASILEA PHARMACEUTICA AG
More recommendations
Financials
Sales 2022 126 M 129 M 129 M
Net income 2022 -42,0 M -43,0 M -43,0 M
Net Debt 2022 108 M 111 M 111 M
P/E ratio 2022 -9,55x
Yield 2022 -
Capitalization 386 M 396 M 396 M
EV / Sales 2022 3,93x
EV / Sales 2023 3,48x
Nbr of Employees 154
Free-Float 87,7%
Chart BASILEA PHARMACEUTICA AG
Duration : Period :
Basilea Pharmaceutica AG Technical Analysis Chart | BSLN | CH0011432447 | MarketScreener
Technical analysis trends BASILEA PHARMACEUTICA AG
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 3
Last Close Price 32,60 CHF
Average target price 77,00 CHF
Spread / Average Target 136%
EPS Revisions
Managers and Directors
David Veitch Chief Executive Officer
Adesh Kaul Head-Corporate Development
Domenico Scala Chairman
Laurenz Kellenberger Chief Scientific Officer
Marc Engelhardt Head-Clinical Research
Sector and Competitors
1st jan.Capi. (M$)
BASILEA PHARMACEUTICA AG-20.33%396
MODERNA, INC.-46.35%54 195
LONZA GROUP AG-27.84%41 796
IQVIA HOLDINGS INC.-28.46%38 202
SEAGEN INC.-9.68%25 704
ICON PUBLIC LIMITED COMPANY-30.22%17 567